Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting ...

Retailers post earnings beats, Bitcoin price hits record, Microsoft conference shows AI progress has slowed, and other news ...

Shares of Merck & Co. Inc. MRK dropped 0.02% to $96.54 Tuesday, on what proved to be an all-around mixed trading session for ...

Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock ...

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...

A study using a Korean database found that COVID-19 infection raised long-term risks for various autoimmune and ...

After decades of disappointment, efforts to create jabs that can stimulate the immune system to fight cancer are showing ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...